Please provide your email address to receive an email when new articles are posted on . The device (TriGuard 3, Keystone Heart) showed potential to prevent larger ischemic brain lesions, Jeffrey W.

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

The Sentinel cerebral protection system (Boston Scientific) was infrequently used during TAVI procedures performed in Germany over a recent 3-year span, and it was not associated with less clinical ...

CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...

Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US and Europe later this year.

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

TAMPA, Florida, March 10, 2020 /PRNewswire/ -- Keystone Heart Ltd., a Venus Medtech Company, today announced European CE Mark for the TriGUARD 3™ Cerebral Embolic Protection (CEP) Device. The device ...

A US Food and Drug Administration (FDA) advisory panel struggled to muster support for marketing clearance of the TriGuard 3 (Keystone Heart) device for use during transcatheter aortic valve ...

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- The "Embolic Protection Devices Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The market is growing ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...